Predicting Lung Toxicity Using Complex In Vitro Models
- Leveraging HiLung’s iPSC‑based technology, we develop lung CIVMs that include organoids as well as immune cells such as tissue‑resident alveolar macrophages to accelerate drug discovery.
- Our system enables pathophysiologically relevant assays through organoid histopathology and biomarker analyses
- Overview of ADC toxicity evaluation at HiLung as an application of lung CIVMs